8-K
filed January 23, 2023, 6:59 PM ET
ticker JAGX
CIK 0001585608
other material
confidence high
sentiment positive
materiality 0.60
Jaguar Health approves 1-for-75 reverse stock split; Phase 3 crofelemer trial to complete Q2 2023
Jaguar Health, Inc.
- Reverse stock split 1-for-75 effective Jan 23, 2023; new CUSIP 47010C706.
- All three stockholder proposals approved at Jan 20 special meeting.
- Pivotal Phase 3 OnTarget trial of crofelemer for CTD; enrollment completion expected Q2 2023.
- Proof-of-concept trial for SBS/CDD underway; potential early access programs in Europe in 2023.
- No fractional shares; cash in lieu; trading continues on Nasdaq under symbol JAGX.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Jaguar Health, Inc.: Filed Seventh Amendment to Certificate of Incorporation to effect a 1-for-75 reverse stock split of common stock (effective 2023-01-23).
- Change
- charter amendment
- Effective
- 2023-01-23
Exact text from the filing
On January 20, 2023, the Company filed the Seventh Amendment with the Secretary of State of the State of Delaware, and the Reverse Stock Split will become effective in accordance with the terms of the Seventh Amendment at 12:01 am Eastern Time on January 23, 2023 (the "Effective Time").
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Jaguar Health, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-3 and not greater than 1-for-75 at the 2023-01-20 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-01-20
Exact text from the filing
Proposal to approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share, at a ratio of not less than 1-for-3 and not greater than 1-for-75, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2024 without further approval or authorization of the Company’s stockholders, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 51,789,833,999 8,053,911,756 237,731,178 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Jaguar Health, Inc. shareholders approved Approve one or more adjournments of the Special Meeting to solicit additional proxies if necessary at the 2023-01-20 meeting.
- Outcome
- passed
- Meeting
- 2023-01-20
Exact text from the filing
Proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1 and 2, was approved by the stockholders by the following vote : For Against Abstained Broker Non- Votes 71,451,220 8,917,441 1,108,272 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Jaguar Health, Inc. shareholders approved Approve issuance of common stock equal to 20% or more of outstanding common stock in one or more non-public capital raising transactions at the 2023-01-20 meeting.
- Outcome
- passed
- Meeting
- 2023-01-20
Exact text from the filing
Proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of Company’s common stock equal to 20% or more the Common Stock outstanding before the issuance in one or more non-public capital raising transaction, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 51,998,893 8,409,585 958,116 20,110,339
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.